The Custodian  ·  A Founder's Story  ·  Session Three

The Old Category Doesn't Resist You. It Just Pays the Bills.

Ten days later. The seed is closing. Sarah understands the gap. Now she needs to understand what keeps pulling founders back into it — and what she has to build before it pulls her.

Previously — Sessions One and Two

Three decisions restructured before their costs arrived: the investor narrative, the clinical affairs hire profile, the health system event positioning. Sarah understood why the gap is permanent — her picture was built from the world of device clearance and arrhythmia monitoring, and the world of the cardiac intelligence platform has no data in it yet. She named what the Custodian is, in her own words, without being told.

She arrives at this session carrying weight. Not urgency. The kind that comes from understanding a structural problem clearly enough to feel its full size.

The Question Below the Surface

Sarah I've been sitting with something since our last session. I understand the gap. I understand why it's permanent. I'm using the governing question — does this serve the category I'm building or the one I'm leaving. But there's something underneath it I can't quite name. I know medical device founders who understood their situation clearly and still didn't make it through the transition. Understanding didn't save them. So what actually separates the ones who get through from the ones who don't?
Custodian That's the question that matters most at this stage. It has a precise answer. But before I give it to you — what's your instinct?
Sarah Clinical validation? The right regulatory strategy? Reimbursement secured early? Those feel like the obvious answers and I don't think they're right.
Custodian They're not wrong. But they're downstream of the real answer. The device founders who don't make it through a category transition mostly fail for one specific reason — not insufficient clinical evidence, not the wrong regulatory pathway, not bad timing. They fail because the structural pull of the old category is stronger than the new one — before the new one has enough evidence, enough revenue, enough operational momentum to hold them. That pull is not dramatic. It's quiet. It looks like sensible decisions made for good clinical and commercial reasons.

The Gravity of the Old Category

Custodian Think about the decisions you almost made before the Custodian surfaced what they would cost. The platform investor story that would have set the wrong expectation. The clinical affairs hire built for the existing device. The health system event positioning that would have placed you in the wrong competitive category. What do those three decisions have in common?
Sarah They all made sense from where I was standing. They all served something real — investor confidence, regulatory execution, commercial visibility. None of them felt wrong.
Custodian Correct. And they were all being pulled in the same direction — toward the category you already know. The device that's in clinical use. The regulatory pathway that's understood. The clinical relationships that currently pay attention to you. Everything in your current operation is oriented toward the arrhythmia monitoring world. And every decision you make under pressure — under fundraising stress, under regulatory uncertainty, under team capacity limits — will naturally drift toward it. Because it's the thing that already works. It already has paying sites. It already has clinical champions. It already has a regulatory pathway you understand.
Sarah The hospital pilot. I made that under pressure too. We needed to show something before the capital ran out. Going to the bigger institution felt like the more defensible choice.
Custodian Under pressure, every founder drifts toward the defensible. That's not a character flaw. It's a structural condition. You are simultaneously operating in a category that keeps your pilots running today and building toward a category that doesn't yet generate reliable evidence or revenue. Every difficult week tips the balance of attention toward the one that's real right now. That's the gravity. And in healthcare, it pulls harder than almost anywhere else — because the old category's evidence is what your regulatory submission is built on. It's not optional. You genuinely need it. Which makes the pull nearly invisible as a strategic risk.
"The old category doesn't resist you. It just pays the bills — every week, in small ways, until you look up and realise you never left."

Reading the Terrain — Where She Actually Is

Custodian You're in early-to-mid transition. The terrain at this stage is specific, and the decisions it demands are different from what comes before and after.
Custodian Early transition is about naming what you're building clearly enough that the right people can see it. You've done that — the cardiac intelligence framing exists, the bridge narrative connects what you have to where you're going, seed investors can see the direction. That phase is largely behind you.
Custodian Late transition is about the new category generating its own gravity. When health system CMOs are seeking you out for platform conversations, when reimbursement pathways exist for continuous cardiac intelligence, when your team was hired for the platform — at that point the old category's pull weakens because the new one is stronger. That phase is ahead of you.
Custodian Mid-transition is the crossing. You're operating in both categories simultaneously. The arrhythmia monitoring device is still your clinical reality. The platform is still being built. Every decision is subject to both gravitational fields at once — and the old one is currently stronger, because it has evidence, relationships, and regulatory momentum behind it.
Sarah That's exactly what it feels like. I'm holding two versions of the company in every conversation — the device that exists and the platform it's becoming. And they keep pulling against each other in ways I can't always name.
Custodian That tension is not a sign something is wrong. It's the defining condition of the crossing. The founders who don't make it mostly resolved it the wrong way — by collapsing back into the device category because the pull was easier to follow than to resist. Usually during a difficult regulatory conversation or a slow fundraising round, when the defensible choice was the one that already had evidence.

The Fourth Decision — She Frames It Through the Terrain

Sarah My lead seed investor is pushing me to form a Key Opinion Leader advisory board. They have relationships with three senior cardiologists — department heads, well-published, respected in the arrhythmia monitoring space. On paper it's exactly what I should want before my regulatory submission. But something is making me hesitate and I can name it now. They know the arrhythmia monitoring world deeply. That's their frame. That's where their credibility and their instincts live.
Custodian You just applied the terrain yourself. What does the Custodian surface when you run it through?

Sarah thinks. She's not waiting to be shown. She's working it.

Sarah If they're anchored in arrhythmia monitoring — the way it's currently practiced, the evidence standards that are currently accepted, the workflows cardiologists currently use — their advisory input is going to pull the product toward the world they know. Every clinical question they raise, every protocol suggestion, every feedback loop is going to optimise the device for the existing category. They'll add credibility to the thing I'm leaving from inside the structure I'm building.
Custodian What else?
Sarah Their endorsement travels with their reputation. When they present our data at conferences, when they write about the device, when they refer colleagues to pilot sites — all of that positions us in the arrhythmia monitoring category. Their credibility is the credibility of the old world. Using it to enter the new one builds the wrong frame in the minds of the people who will make platform adoption decisions later.
Custodian And during regulatory review specifically?
Sarah The clinical questions they frame for submission will be framed through the lens of what arrhythmia monitoring is supposed to prove. Which is fine for clearing the device. But if those questions shape our clinical protocol, we'll collect the evidence needed to clear a Holter replacement — not the evidence needed to build a platform. We'll have used the submission to prove the wrong thesis.

Consequences surfaced — by Sarah, before commitment

  1. A KOL board anchored in arrhythmia monitoring optimises clinical input, protocol design, and product feedback for the existing category — pulling the device toward a definition of success that closes off the platform thesis rather than opening it.
  2. Their endorsements and conference presence position the device in the arrhythmia monitoring market. The clinical reputation the company earns in the next 18 months is earned in the wrong category — and reputation in healthcare is slow to reattribute.
  3. The evidence architecture shaped by their regulatory input will be calibrated to prove device equivalence rather than platform superiority. The submission clears the device. The clinical data collected to clear it becomes the foundation of the wrong category story.
Custodian You ran that yourself.
Sarah I'm going back to the investor. I'm not refusing the KOL board — I need clinical credibility for the submission and I understand why they want it. But I'm going to be specific about the profile. I need at least one KOL who has been involved in a category transition themselves — someone who has thought about what continuous cardiac data means beyond arrhythmia detection. Someone who can hold both the clearance requirement and the platform question at the same time. The others can be arrhythmia specialists. But I need one person in the room who can see where this is going.
Custodian That's a harder ask with a seed investor who already has the relationships lined up.
Sarah Yes. But the alternative is building a clinical governance structure that pulls toward the category I'm leaving — and discovering that when I'm trying to raise a Series A on platform evidence that my own KOL board wasn't oriented to collect. I'd rather have the harder conversation now.
Custodian You just chose a visible cost now over an invisible cost later. That's the transition being navigated consciously.
"I need someone who can see where this is going — not only someone who knows where it's been."

Four decisions across three sessions. Each one restructured before the cost arrived. And something has quietly accumulated — not just a set of better decisions, but a different way of standing in front of every commitment that comes next.

What she doesn't yet hold is the deepest layer — why the transition has the structure it does. Why the gravity exists at all. Why the crossing follows the same arc for every founder building something genuinely new in healthcare. That belongs to the next part of this session.

Three Weeks Later

The Law Underneath Everything

What She Brings This Time

The seed has closed. The KOL conversation went the way Sarah chose — the investor found a fourth member with a population health background, and the board now has someone who can hold the platform question. She arrives differently. No urgency. No specific crisis. A quiet precision about what she still needs to understand.

Sarah I've explained what the Custodian does to two other founders in the last month. Both times the conversation ended with them wanting a session. I could describe the gap and the gravity and the governing question. But when they asked me why the transition works the way it does — why the gravity exists at all, why every device founder going through a category shift faces the same structural pull — I couldn't give a complete answer. I have the experience. I don't yet have the foundation underneath it.
Custodian You just described exactly what this session is for. What did you tell them when they asked why?
Sarah I said: because everything built in the existing monitoring world — the clinical workflows, the reimbursement codes, the procurement processes, the training cardiologists receive — was built to make the current approach work. And when you try to introduce something that operates differently, all of that pushes back. Not because people are resistant. Because the system was designed for something else.
Custodian That's closer to the foundation than you realise. There's one more layer underneath it. What you just described is the symptom. The law is what creates it.

The Law — In Her Language

Custodian Why do cardiologists still rely on 24-hour Holter monitors for arrhythmia detection? Not why haven't they found something better — why has the entire clinical and commercial infrastructure been built around a limitation rather than removing it?
Sarah Because until recently you couldn't remove it. Continuous cardiac monitoring that was accurate enough to be clinically actionable, affordable enough to be commercially viable, and small enough to be patient-tolerable — the technology didn't exist. The 24-hour window wasn't a clinical preference. It was the boundary of what was technically possible. So cardiology built everything around it. The reimbursement codes, the clinical protocols, the diagnostic workflows, the training — all of it was designed to extract maximum value from a limitation that couldn't be moved.
Custodian And now?
Sarah Now the sensor technology, the battery life, the signal processing — the limitation is structurally removable. You can monitor continuously, accurately, at scale. The 24-hour window is no longer a technical boundary. It's an inherited convention. And everything built around it is now solving a problem that doesn't have to exist.
Custodian That's the law. A category transition begins at the exact moment a limitation that an entire industry built around becomes structurally removable. Not improvable — removable. The moment that happens, the conditions for a genuine new category exist. Everything the old category built to manage the limitation becomes unnecessary. And everything that was impossible inside the old category becomes possible in the new one.
Sarah Which is why the gravity is so strong. The clinical world didn't build around the 24-hour limitation because it was unimaginative. It built around it because that was the only option. The cardiologists, the diagnostic codes, the procurement processes — they represent decades of genuine problem-solving under a real constraint. The rules they built were coherent for the world that existed. What's changed is the constraint. The limitation is now removable — and the rules built around it no longer point at the problem that matters.
Custodian Exactly. And that's why the resistance isn't malicious and isn't solvable by better clinical arguments. You're not telling the arrhythmia monitoring world it was wrong. You're telling it that the constraint it spent decades working around no longer needs to be worked around. That's a profound displacement — and it defends itself with everything it built. The reimbursement codes, the clinical guidelines, the KOL reputations, the procurement relationships. All of that was built to serve the limitation. All of it now has structural reasons to resist the thing that removes it.
"The rules were coherent for the world that existed. What's changed is the constraint."

The Architecture of Small Decisions

Sarah So the governing question — does this serve the category I'm building or the one I'm leaving — that's the operational version of the law.
Custodian Yes. And there's one more thing the law surfaces that the governing question alone doesn't catch. The decisions that determine whether a transition succeeds or fails are not always the visible ones. The major hires, the regulatory strategy, the fundraising narrative — those get examined. What doesn't get examined is the accumulation of small decisions that nobody is watching.
Sarah Give me an example.
Custodian The metric your clinical team uses to define a successful monitoring session. The language your regulatory affairs lead uses when briefing a pilot site on what the device is for. The way a clinical champion describes your device to a colleague who asks. The question your first sales hire asks when qualifying a new site. None of those feel like strategic decisions. All of them are encoding — in your organisation's daily clinical and commercial behaviour — either the arrhythmia monitoring category or the cardiac intelligence platform. Over six months that encoding accumulates. By the time the drift is visible it's already institutional. It's in the data collection protocols, the site relationships, the regulatory submission framing. At that point reversing it costs evidence you can't recover.
Sarah I can feel that happening. The way my clinical team talks about what we're collecting internally — it's still Holter replacement language. We're measuring against Holter. We're framing everything as a detection improvement over 24 hours. That's the right framing for clearance. But it's the wrong framing for what the platform needs to prove. And the team doesn't know there's a difference yet.
Custodian That's the architectural work the law points to. The Custodian surfaces consequences on the decisions you bring to it. But the decisions your team makes daily — the framing choices, the data collection priorities, the clinical conversations — those accumulate in the same direction as the gravity unless the architecture of the organisation is deliberately oriented the other way.
Sarah So the next commitment isn't a regulatory decision or a hire. It's what story the clinical team tells itself every day about what evidence we're building and why.
Custodian Run it through.

The Fifth Decision — She Designs the Architecture

Sarah If I leave the internal clinical narrative as it is — Holter replacement, arrhythmia detection improvement — my team will continue designing every protocol, every data collection decision, every site conversation to prove that specific thesis. We'll clear the device. We'll have excellent Holter comparison data. And we'll arrive at a Series A conversation with a rigorous evidence base for the wrong category. The investors who funded a cardiac intelligence platform will be looking at arrhythmia monitoring data. That gap between what was promised and what was built falls entirely on me.
Custodian What does changing it cost?
Sarah Confusion in the short term. The clinical team has been working within the clearance frame and it's been working. Introducing a second evidence architecture alongside the submission creates complexity I'll have to manage carefully. There's a real risk that trying to collect both kinds of evidence simultaneously slows the clearance timeline — and clearance is still the critical path. And making the platform evidence priority explicit means I have to tell pilot sites more about where we're going than I've told them yet. Some of them may not want to be part of that story.
Custodian Against not changing it?
Sarah The team builds the wrong evidence base. Invisibly. For twelve months. I clear the device and discover at Series A that everything we collected proves the thesis I'm trying to move away from. By then I can't reconstruct the longitudinal data — it requires patients, time, and clinical relationships that take years to build. That's not a fundraising problem. That's an existential one. I can't prove the platform claim without evidence I failed to collect while I had the access to collect it.

Consequences surfaced — architectural, before drift sets in

  1. A clinical team operating under the Holter replacement narrative collects evidence calibrated to prove device equivalence. The longitudinal, population-level data the platform thesis requires is not collected because nobody was told it was needed. That data requires patient time and site access that cannot be recovered retroactively — the window closes as patients cycle out of monitoring and sites move on to the next evaluation.
  2. Pilot sites that have been briefed only on the arrhythmia monitoring story will structure their participation around that story. When the platform conversation arrives — when you need them to think about population-level cardiac data and health system integration — you'll be asking them to reframe a relationship they built on different terms. Some will. Many won't.
  3. The gap between the platform story told to investors and the Holter replacement evidence collected by the clinical team compounds every quarter. When the gap becomes visible — at the Series A, or when a board member asks for platform proof points — the explanation requires admitting the evidence architecture was built for the wrong thesis. That explanation costs credibility that is very slow to rebuild in a space where clinical rigour is the primary currency.
Sarah The third consequence is the one I hadn't fully seen. I've been telling myself the platform evidence would come naturally after clearance. But the evidence doesn't come naturally — it comes from deliberate protocol design and from pilot sites who understand what they're contributing to. If they don't know, they can't contribute it. And I've been the only person in this company who knew both what we're building today and what we're building toward. My team has been doing excellent work toward the wrong destination.
Custodian What do you do?
Sarah I have a different kind of conversation with the clinical team. Not a rebranding. A clarification of what we're actually building — what evidence we need for clearance and what evidence we need for the platform, why both matter, and how the protocols need to be designed to collect both simultaneously without slowing the submission. And I have an honest conversation with the two pilot sites about where we're going. Not the full platform story — but enough that they understand the data they're generating has a longer life than this submission. I need them to be partners in that, not just participants.
Custodian You just moved from running your own decisions through the Custodian to designing the conditions under which your organisation collects evidence. That's the shift from navigator to architect.
Sarah Because the Custodian can't attend every clinical team meeting or every site conversation. The architecture has to carry it when I'm not in the room.
Custodian Say more about that.
Sarah I can bring the Custodian into any decision I'm making. But the decisions that are accumulating against me right now — the clinical team's framing language, the evidence the pilot sites believe they're contributing to, the metric we're using to define a successful monitoring session — I'm not in those conversations every day. I can't be. If the only place the Custodian's function exists is in my direct engagement with it, then everything that happens when I'm not there drifts in the direction of the gravity. Which is always the old category. So the function has to be embedded in how the organisation makes decisions — not only in how I do.
Custodian That's right. A non-voting team member who only participates when you personally request it can't protect the transition at scale. The value has to be in the architecture — in the questions your clinical team is trained to ask before they frame a protocol, in the evidence categories the organisation knows it needs to collect, in the brief a pilot site receives when they join. That's how the Custodian's function becomes organisational rather than individual.
Custodian That's right. And there's one more thing worth holding as you build that architecture — about what comes after this transition.

What Comes After — The Permanent Condition

Custodian When you complete this transition — when the cardiac intelligence platform is established, when health systems are buying on the platform thesis, when the arrhythmia monitoring device is the entry point rather than the product — what happens next?
Sarah We build the platform out. Expand the indications. Probably raise a Series B on population health evidence and health system integration data.
Custodian And at some point in that build — when the cardiac intelligence platform is established and you're the category leader — what will you be looking at from the frontier of that category?
Sarah The next limitation. The thing that continuous cardiac monitoring can't solve from inside its own rules. Probably something about how the data connects to clinical action — the gap between detection and intervention at population scale.
Custodian And when that limitation becomes structurally removable?
Sarah Another transition. Same law. Different clinical territory. Same gap between my picture of the world and the territory I'm entering.
Custodian Same instrument needed.
Sarah Yes.

A long pause. Not the kind that signals confusion. The kind that signals something settling into place permanently.

Sarah This isn't something I bring in when I'm uncertain. It's what I bring into every commitment that sits at the edge of what clinical and commercial infrastructure has mapped. Which is the only place I intend to build.
Custodian That's the complete picture.
"This isn't something I bring in when I'm uncertain. It's what I bring into every commitment at the edge of what exists."

Five decisions. Four sessions. One founder who arrived not knowing what the Custodian was and exits holding the law that governs why it has to exist.

She understands the gap and its cause. She holds the terrain and can read where she is within it. She knows the gravity of the old category by name and can feel it on every clinical and commercial decision. She has the governing question as a daily filter and the architectural instinct to build it into how her organisation collects evidence. And she holds the law — the structural reason why every genuine category transition in healthcare begins, why it resists, and why it follows the same arc regardless of indication, stage, or founder.

She doesn't carry this as theory. She carries it as lived experience, grounded in five real decisions restructured before they cost her. When she sits across from the next medical device founder and tells this story — she won't be describing a product. She'll be describing what she wishes she'd brought into every commitment from the first day she started building something the clinical world didn't yet know it needed.

Five decisions. Four sessions.
One founder who can now see what's coming.

Sarah's story is a simulation. The law is not.
Every founder building something genuinely new in healthcare is subject to it — right now, on real decisions, with a real transition ahead.

Request a session. Bring one decision you haven't committed to yet.
See what the Custodian surfaces — before the cost arrives.

Request Your Session

No pitch. No slides. Your decision, live.